Fortitude Biomedicines

Fortitude Biomedicines is a biotechnology company based in Waltham, Massachusetts, that develops immune cell targeting biologics and next-generation antibody-drug conjugates for the treatment of autoimmune diseases and cancers. The enterprise utilizes a proprietary GLUE-DAC platform that incorporates molecular glue payloads to address resistance challenges associated with current therapeutic options. Operating as a seed-stage venture, the firm has secured $13 million in initial financing to advance its lead biologic candidate through investigational new drug-enabling studies while expanding its core platform. This funding round was co-led by institutional investors K2 Bio Partners, Shanghai Healthcare Angel Capital, and Elikon Venture, with additional participation from Everjoy Fortune and Taihill Venture. The organization's board of directors includes industry veteran Tim Noyes as chair. Fortitude Biomedicines was recently founded by Jesse Chen, who serves as President and Chief Executive Officer, alongside Jin Wang.